PHOSLO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Phoslo, and what generic alternatives are available?
Phoslo is a drug marketed by Fresenius Medcl and is included in two NDAs.
The generic ingredient in PHOSLO is calcium acetate. There are two hundred and eighty-two drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the calcium acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Phoslo
A generic version of PHOSLO was approved as calcium acetate by HIKMA on February 26th, 2008.
Summary for PHOSLO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 60 |
| Clinical Trials: | 7 |
| Patent Applications: | 235 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for PHOSLO |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PHOSLO |
| What excipients (inactive ingredients) are in PHOSLO? | PHOSLO excipients list |
| DailyMed Link: | PHOSLO at DailyMed |
Recent Clinical Trials for PHOSLO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Amgen | N/A |
| Azienda Ospedaliera Sant'Anna | N/A |
| Albany Medical College | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for PHOSLO
US Patents and Regulatory Information for PHOSLO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Medcl | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-001 | Apr 2, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Medcl | PHOSLO GELCAPS | calcium acetate | CAPSULE;ORAL | 021160-003 | Apr 2, 2001 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Medcl | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-002 | Apr 2, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Medcl | PHOSLO | calcium acetate | TABLET;ORAL | 019976-001 | Dec 10, 1990 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PHOSLO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Fresenius Medcl | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-001 | Apr 2, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Fresenius Medcl | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-002 | Apr 2, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Fresenius Medcl | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-002 | Apr 2, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Fresenius Medcl | PHOSLO | calcium acetate | TABLET;ORAL | 019976-001 | Dec 10, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PHOSLO
See the table below for patents covering PHOSLO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1333884 | FIXATEUR DE PHOSPHORE (PHOSPHOROUS BINDER) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PHOSLO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2365988 | CA 2018 00006 | Denmark | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
| 2365988 | 122018000012 | Germany | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM UND SALZE DAVON IN ALLEN VOM GRUNDPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/17/1179 20170719 |
| 0720599 | 300689 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
| 0521471 | C300125 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106 |
| 2365988 | 2018C/006 | Belgium | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM OF EERDER WELK ZOUT OF AFGELEIDE ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
| 0720599 | 122014000088 | Germany | ⤷ Sign Up | PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT ATORVASTATIN ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE ATORVASTATIN ALS ATORVASTATINCALCIUMTRIHYDRAT; NAT. REGISTRATION NO/DATE: 90223.00.00 20141113; FIRST REGISTRATION: FRANKREICH CIS: 6 928 917 6 20140912 |
| 2957286 | 1990003-4 | Sweden | ⤷ Sign Up | PRODUCT NAME: PATRIOMER SORBITEX CALCIUM; REG. NO/DATE: EU/1/17/1179 20170721 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
